Alan P. Venook, MD

Rutgers College, New Brunswick, New Jersey, BA, 1976, Biological Sciences
University of California San Francisco, MD, 1980, Medicine
University of California San Francisco, Internship, 1981, Internal Medicine
University of California, Davis, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1987, Hematology/Oncology

• 1980
  Assistant Clinical Professor of Medicine, UCSF
• 1994-2000
  Associate Professor of Clinical Medicine, UCSF
• 1997-2004
  Director, Clinical Research Support Services Core, UCSF Comprehensive Cancer Center
• 2004-2007
  Associate Chief, Division of Medical Oncology, UCSF
• 2004- present
  Member, Executive Policy Group of the Human Research Protection Program
• 2005-present
  Chairman, UCSF Committee on Human Research
• 2005-present
  Chairman, Cancer Center Data Safety Monitoring Committee
• 2008- 2010
  Director, Regulatory Knowledge and Support Program of the UCSF Clinical and Translational Science Institute
• 2008-present
  Member, Research Administration Board
• 2000-present
  Professor of Clinical Medicine, UCSF

• 1999
  Mention-Colon Cancer-Medical Oncologist, Top Cancer Specialsts, Good Housekeeping
• 1999
  Mention-Medical Oncology and Hematology, Top 425 Doctors in the Bay Area, San Francisco

• Allegra A, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol N, Saltz L, Venook A, Yothers G, Sargent D: End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. Aug 20 (25):3572-75, 2007. PMID: 17704403
• Posner MD, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM: A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group b study 89903. Ann Surg Oncol. Nov 16, 2007. PMID 18008108
• O’Neil B, Venook AP: Hepatocellular carcinoma, the role of the North American GI steering committee hepatobiliary task force, and the advent of the effective drug therapy. Oncologist. Dec; 12: 1425-1432, 2007. PMID 18165619
• Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. Jan 7(1):44-7, 2008. PMID 18279576
• Figlin RA, Brown E, Armstrong A, Akerley W, Berson AB, Burstein HJ, Ettinger DS, Febbbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task force report: mTOR inhibition in solid tumors. J of the NCCN. Sept, 6 (5), 2008. PMID 18926092
• Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. Dec 20;26(36):5845-8, 2008. PMID 19029408
• Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guideline in oncology: hepatobiliary cancers. J Natl Canc Netw.; Apr;7(4):350-91, 2009. PMID: 19406039
• Kelley R, Venook AP. Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep. May; 11(3):175-85, 2009. PMID: 19336009
• Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Diawari, RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Roa S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clincal practice guidelines in oncology: rectal cancer. J Natl Canc Netw.;Sept;7(8):838-81, 2009. PMID: 19755047
• Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Diawari, RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Roa S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clincal practice guidelines in oncology: colon cancer. J Natl Canc Netw.;Sept;7(8):788-831, 2009. PMID: 19755046
• Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg; 145 (3): 276-80, 2010. PMID: 20231629
• Lencioni R, Marrero J, Venook A, Ye S-L, Kudo M. Design and rationale for the non-interventional investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract. July (64), 8, 1034-41, 2010. PMID: 20642705
• Kelley RK, Venook AP, Nonadherence to Imatinib during an economic downturn. N Engl J Med. Aug 5, 596-98, 2010. PMID: 20818898
• Roberts JP, Venook A, Kerlan R. Yao, F. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl. 16:925-29, 2010. PMID: 20658555
• Kelley RK, Van Bebber SL, Phillips KA, Venook AP, Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. JNCCN. 9;13-25, 2011.